Titre : Catéchine

Catéchine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Combined Modality Therapy

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment mesurer les niveaux de catéchines dans le corps ?

Les niveaux de catéchines peuvent être mesurés par des analyses sanguines ou urinaires.
Catéchines Analyse sanguine
#2

Quels tests sont utilisés pour évaluer l'impact des catéchines ?

Des tests cliniques et des études d'observation sont utilisés pour évaluer leur impact.
Catéchines Études cliniques

Symptômes 2

#1

Quels sont les effets secondaires des catéchines ?

Les effets secondaires peuvent inclure des maux d'estomac, des nausées ou des maux de tête.
Effets secondaires Catéchines
#2

Les catéchines provoquent-elles des allergies ?

Les allergies aux catéchines sont rares, mais peuvent survenir chez certaines personnes.
Allergies Catéchines

Prévention 2

#1

Les catéchines aident-elles à prévenir les maladies cardiaques ?

Oui, elles peuvent réduire le risque de maladies cardiaques en améliorant la santé vasculaire.
Maladies cardiaques Prévention
#2

Comment intégrer les catéchines dans l'alimentation ?

Consommer du thé vert, des fruits et des légumes riches en catéchines est recommandé.
Alimentation Catéchines

Traitements 2

#1

Les catéchines peuvent-elles traiter des maladies ?

Elles sont étudiées pour leur potentiel dans le traitement de maladies comme le cancer.
Traitement du cancer Catéchines
#2

Comment les catéchines aident-elles à la perte de poids ?

Elles peuvent augmenter le métabolisme et favoriser la combustion des graisses.
Perte de poids Métabolisme

Complications 2

#1

Les catéchines peuvent-elles interagir avec des médicaments ?

Oui, elles peuvent interagir avec certains médicaments, notamment les anticoagulants.
Interactions médicamenteuses Catéchines
#2

Quels risques sont associés à une consommation excessive de catéchines ?

Une consommation excessive peut entraîner des problèmes hépatiques ou des troubles digestifs.
Toxicité Catéchines

Facteurs de risque 2

#1

Qui devrait éviter les catéchines ?

Les personnes ayant des problèmes hépatiques ou des allergies doivent être prudentes.
Facteurs de risque Catéchines
#2

Les femmes enceintes peuvent-elles consommer des catéchines ?

Elles doivent consulter un médecin avant de consommer des catéchines en grande quantité.
Grossesse Catéchines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Catéchine : Questions médicales les plus fréquentes", "headline": "Catéchine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Catéchine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Catéchine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Flavonoïdes", "url": "https://questionsmedicales.fr/mesh/D005419", "about": { "@type": "MedicalCondition", "name": "Flavonoïdes", "code": { "@type": "MedicalCode", "code": "D005419", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.150.266.450" } } }, "about": { "@type": "MedicalCondition", "name": "Catéchine", "alternateName": "Catechin", "code": { "@type": "MedicalCode", "code": "D002392", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jae Sik Yu", "url": "https://questionsmedicales.fr/author/Jae%20Sik%20Yu", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea." } }, { "@type": "Person", "name": "Ki Hyun Kim", "url": "https://questionsmedicales.fr/author/Ki%20Hyun%20Kim", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea." } }, { "@type": "Person", "name": "Masaharu Shin-Ya", "url": "https://questionsmedicales.fr/author/Masaharu%20Shin-Ya", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } }, { "@type": "Person", "name": "Eriko Ohgitani", "url": "https://questionsmedicales.fr/author/Eriko%20Ohgitani", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } }, { "@type": "Person", "name": "Masaya Kawamoto", "url": "https://questionsmedicales.fr/author/Masaya%20Kawamoto", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.", "datePublished": "2023-08-06", "url": "https://questionsmedicales.fr/article/37586927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clcc.2023.08.002" } }, { "@type": "ScholarlyArticle", "name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36351568", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14724" } }, { "@type": "ScholarlyArticle", "name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.", "datePublished": "2022-07-17", "url": "https://questionsmedicales.fr/article/35963771", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clml.2022.07.005" } }, { "@type": "ScholarlyArticle", "name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36102865", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DCR.0000000000002600" } }, { "@type": "ScholarlyArticle", "name": "PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).", "datePublished": "2022-09-10", "url": "https://questionsmedicales.fr/article/36099671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejca.2022.07.027" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzopyranes", "item": "https://questionsmedicales.fr/mesh/D001578" }, { "@type": "ListItem", "position": 6, "name": "4H-1-Benzopyran-4-ones", "item": "https://questionsmedicales.fr/mesh/D002867" }, { "@type": "ListItem", "position": 7, "name": "Flavonoïdes", "item": "https://questionsmedicales.fr/mesh/D005419" }, { "@type": "ListItem", "position": 8, "name": "Catéchine", "item": "https://questionsmedicales.fr/mesh/D002392" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Catéchine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Catéchine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Catéchine", "description": "Comment mesurer les niveaux de catéchines dans le corps ?\nQuels tests sont utilisés pour évaluer l'impact des catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Catéchine", "description": "Quels sont les effets secondaires des catéchines ?\nLes catéchines provoquent-elles des allergies ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Catéchine", "description": "Les catéchines aident-elles à prévenir les maladies cardiaques ?\nComment intégrer les catéchines dans l'alimentation ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Catéchine", "description": "Les catéchines peuvent-elles traiter des maladies ?\nComment les catéchines aident-elles à la perte de poids ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Catéchine", "description": "Les catéchines peuvent-elles interagir avec des médicaments ?\nQuels risques sont associés à une consommation excessive de catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Catéchine", "description": "Qui devrait éviter les catéchines ?\nLes femmes enceintes peuvent-elles consommer des catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer les niveaux de catéchines dans le corps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de catéchines peuvent être mesurés par des analyses sanguines ou urinaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'impact des catéchines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests cliniques et des études d'observation sont utilisés pour évaluer leur impact." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des catéchines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des maux d'estomac, des nausées ou des maux de tête." } }, { "@type": "Question", "name": "Les catéchines provoquent-elles des allergies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies aux catéchines sont rares, mais peuvent survenir chez certaines personnes." } }, { "@type": "Question", "name": "Les catéchines aident-elles à prévenir les maladies cardiaques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent réduire le risque de maladies cardiaques en améliorant la santé vasculaire." } }, { "@type": "Question", "name": "Comment intégrer les catéchines dans l'alimentation ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Consommer du thé vert, des fruits et des légumes riches en catéchines est recommandé." } }, { "@type": "Question", "name": "Les catéchines peuvent-elles traiter des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont étudiées pour leur potentiel dans le traitement de maladies comme le cancer." } }, { "@type": "Question", "name": "Comment les catéchines aident-elles à la perte de poids ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent augmenter le métabolisme et favoriser la combustion des graisses." } }, { "@type": "Question", "name": "Les catéchines peuvent-elles interagir avec des médicaments ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec certains médicaments, notamment les anticoagulants." } }, { "@type": "Question", "name": "Quels risques sont associés à une consommation excessive de catéchines ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une consommation excessive peut entraîner des problèmes hépatiques ou des troubles digestifs." } }, { "@type": "Question", "name": "Qui devrait éviter les catéchines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des problèmes hépatiques ou des allergies doivent être prudentes." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles consommer des catéchines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles doivent consulter un médecin avant de consommer des catéchines en grande quantité." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Jae Sik Yu

2 publications dans cette catégorie

Affiliations :
  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Publications dans "Catéchine" :

Ki Hyun Kim

2 publications dans cette catégorie

Affiliations :
  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Publications dans "Catéchine" :

Masaharu Shin-Ya

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Molecular Anti-Virus Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Eriko Ohgitani

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masaya Kawamoto

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masaki Ichitani

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Anti-Virus Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Central Research Institute, ITO EN, Ltd, Shizuoka, Japan.

Makoto Kobayashi

2 publications dans cette catégorie

Affiliations :
  • Central Research Institute, ITO EN, Ltd, Shizuoka, Japan.

Takanobu Takihara

2 publications dans cette catégorie

Affiliations :
  • Central Research Institute, ITO EN, Ltd, Shizuoka, Japan.

Hitoshi Kinugasa

2 publications dans cette catégorie

Affiliations :
  • Central Research Institute, ITO EN, Ltd, Shizuoka, Japan.

Osam Mazda

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan. mazda@koto.kpu-m.ac.jp.
  • Department of Molecular Anti-Virus Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan. mazda@koto.kpu-m.ac.jp.

Chang Liu

2 publications dans cette catégorie

Affiliations :
  • Tea Science Society of China, Hangzhou, China.
Publications dans "Catéchine" :

Jian-Hui Ye

2 publications dans cette catégorie

Affiliations :
  • Tea Research Institute, Zhejiang University, Hangzhou, China.
Publications dans "Catéchine" :

Penghui Li

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Tea Science of Ministry of Education, Hunan Agricultural University, Changsha, Hunan, China.
  • National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, Collaborative Innovation Centre of Utilisation of Functional Ingredients from Botanicals, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Ailing Liu

2 publications dans cette catégorie

Affiliations :
  • College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Wenjun Xiao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Tea Science of Ministry of Education, Hunan Agricultural University, Changsha, Hunan, China.
  • National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, Collaborative Innovation Centre of Utilisation of Functional Ingredients from Botanicals, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Jianan Huang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Tea Science of Ministry of Education, Hunan Agricultural University, Changsha, Hunan, China.
  • National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, Collaborative Innovation Centre of Utilisation of Functional Ingredients from Botanicals, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Sheng Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Tea Science of Ministry of Education, Hunan Agricultural University, Changsha, Hunan, China.
  • National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, Collaborative Innovation Centre of Utilisation of Functional Ingredients from Botanicals, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Zhonghua Liu

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Tea Science of Ministry of Education, Hunan Agricultural University, Changsha, Hunan, China.
  • National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, Collaborative Innovation Centre of Utilisation of Functional Ingredients from Botanicals, Hunan Agricultural University, Changsha, Hunan, China.
Publications dans "Catéchine" :

Zvezdelina Yaneva

2 publications dans cette catégorie

Affiliations :
  • Chemistry Unit, Department of Pharmacology, Animal Physiology and Physiological Chemistry, Faculty of Veterinary Medicine, Students Campus, Trakia University, 6000 Stara Zagora, Bulgaria.
Publications dans "Catéchine" :

Donika Ivanova

2 publications dans cette catégorie

Affiliations :
  • Chemistry Unit, Department of Pharmacology, Animal Physiology and Physiological Chemistry, Faculty of Veterinary Medicine, Students Campus, Trakia University, 6000 Stara Zagora, Bulgaria.
Publications dans "Catéchine" :

Sources (10000 au total)

Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.

We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC).... This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s... Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ... Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...

Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.

The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria... This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe... We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi... For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....

Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.

There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer.... This study aimed to evaluate long-term changes in patients treated with combined modality.... This was a retrospective study of prospectively collected patient-reported outcome surveys.... This study was conducted at a single institution.... There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey.... This study included patient-reported outcomes reflecting bowel, sexual, and urinary function.... Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9... This was a single-institution study and only patients who answered the questionnaire were included in the study.... A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was... ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...

PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).

Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder... Patients underwent baseline... In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien... The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder... NCT00002014-000860-16....

Neurotoxins and Combination Therapies.

Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often... To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans.... This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ... Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme... Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...

Combination therapies for cancer: challenges and opportunities.

Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti... Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel... Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma (HCC). The synergistic effect of systemic therapy and radia... This retrospective observational study analyzed the medical records of 194 patients with Barcelona Clinic Liver Cancer stage C HCC who were admitted to our center from August 2018 to June 2022 and rec... A total of 76 patients diagnosed with advanced-stage HCC and treated with ICIs and antiangiogenic therapy were included in the study, with 33 patients in the RT group and 43 patients in the non-RT gro... In comparison to the combination of ICIs and antiangiogenic therapy, the inclusion of RT has been observed to improve the DCR and survival outcomes in patients with advanced-stage HCC. The safety prof...